2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515: 563-567. PMID: 25428504, PMCID: PMC4836193, DOI: 10.1038/nature14011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenBiomarkersChemokine CX3CL1Clinical ProtocolsCTLA-4 AntigenDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansImmunotherapyLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasmsTreatment OutcomeYoung AdultCirculating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A
Kowanetz M, Rabe C, Xiao Y, Wu Q, Koeppen H, Leddy C, Patel R, Powderly J, Kohrt H, Gettinger S, Soria J, Herbst R, Desai R, Denker M, Ruppel J, Boe M, Nakamura R, Fu L, Sumiyoshi T, Mokatrin A, Shen X, Fine G, Chen D, Hegde P. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A. Journal For ImmunoTherapy Of Cancer 2014, 2: p136. PMCID: PMC4288453, DOI: 10.1186/2051-1426-2-s3-p136.Peer-Reviewed Original ResearchP13. Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A)
Kowanetz M, Vu M, Wu J, Koeppen H, Kohrt H, Gettinger S, Cruz C, Denker M, Chen D, Hegde P. P13. Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A). Journal For ImmunoTherapy Of Cancer 2014, 2: p4. PMCID: PMC4072139, DOI: 10.1186/2051-1426-2-s2-p4.Peer-Reviewed Original Research
2013
Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1
Kohrt H, Kowanetz M, Gettinger S, Powderly J, Koeppen H, Sosman J, Cruz C, Xiao Y, Mokatrin A, Fine G, Chen D, Hodi F. Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1. Journal For ImmunoTherapy Of Cancer 2013, 1: o12. PMCID: PMC3991257, DOI: 10.1186/2051-1426-1-s1-o12.Peer-Reviewed Original Research